Taken in the context of our current and prior findings showing CBX2 is critical for HGSC progression (6), targeting CBX2 in tumor cells provides an opportunity to limit tumor progression and potentially alleviate an immune-suppressed microenvironment. This evidence concerns the gene CBX2 and neoplasm.